Masters of Longevity - The Pulse

traderVC19 Jun 2026
Traded: Venture Capital 🦄 on Instagram: "Houdini Bio has emerged from stealth with $1.95 million in pre-seed funding led by SCVC, with participation from Deep...

Traded: Venture Capital 🦄 on Instagram: "Houdini Bio has emerged from stealth with $1.95 million in pre-seed funding led by SCVC, with participation from Deep Science Ventures and Cambridge Enterprise Ventures, to develop a DNA engineering platform designed to improve the durability and effectiveness of gene therapies. Founded in 2025, the British biotech startup combines machine learning with research into cellular DNA silencing mechanisms to help therapeutic genes evade biological defenses that can reduce treatment efficacy. The company says its platform can increase gene expression by more than tenfold compared to existing approaches, with potential applications across conditions including cystic fibrosis, haemophilia, cancer, dementia, and inherited blindness. FOUNDERS: Jonathan Cohen-Gold & Lee Dunham INVESTORS: SCVC, Deep Science Ventures & Cambridge Enterprise Ventures ROUND: Pre-Seed AMOUNT: $1,950,000 HQ: Cambridge, United Kingdom #VentureCapital #HoudiniBio #JonathanCohenGold #SCVC #DeepScienceVentures TradedVC"

Startup profile focusing on founders, financing and scientific strategy behind a biotech's debut, offering context for investors and scientific readers.

Key takeaways
  • Houdini Bio secured $1.95 million pre-seed funding to pursue therapies for cystic fibrosis.
  • Houdini Bio is developing a DNA-engineering platform combining machine learning with DNA-silencing research.
  • Company reports the platform increases gene expression more than tenfold versus current approaches.
Fight Aging!19 Jun 2026
AIA Combination Senolytic and Stem Cell Therapy Assessed in a Mouse Model of Aging (Fight Aging!)

A Combination Senolytic and Stem Cell Therapy Assessed in a Mouse Model of Aging

Curious about experimental approaches that clear dysfunctional aging cells while promoting regeneration? This article assesses recent preclinical research, methods, and translational caveats.

Key takeaways
  • Study used accelerated-aging and organ-injury mouse models rather than natural aging.
  • Researchers employed a senolytic vaccine instead of small-molecule senolytic drugs.
  • Combining senolytic immunotherapy with personalized MSCs markedly extended healthspan and lifespan.
Youtube — Human Longevity19 Jun 2026
7 Reasons You Can’t Afford Not to Sequence Your Genome with Dr. Wei-Wu He | Webinar (Youtube — Human Longevity)

7 Reasons You Can’t Afford Not to Sequence Your Genome with Dr. Wei-Wu He | Webinar

An advocate's case for routine genome sequencing framed around longevity opportunities, clinical prevention, and democratizing precision health.

Key takeaways
  • Average life expectancy rose to about eighty years in developed countries due to antibiotics and vaccines.
  • HPV vaccination and Pap smear screening have cut cervical cancer deaths by eighty to ninety percent.
  • Approximately three hundred thousand women worldwide still die from cervical cancer each year.
Lifespan.io19 Jun 2026
Epigenetic Drug Targets Fat, Improving Blood Vessel Health (Lifespan.io)

Epigenetic Drug Targets Fat, Improving Blood Vessel Health

Clinicians and curious readers will find an upbeat, accessible summary of new laboratory research and its potential cardiovascular implications.

Key takeaways
  • Epigenetic drug can target fat surrounding blood vessels to alter local tissue behavior.
  • Modifying perivascular fat with the drug improved vascular health indicators in experimental models.
  • Targeting perivascular adipose tissue may offer a new avenue for cardiometabolic therapies.